China COVID-19 drugs pipeline focuses on new variants amidst rising concerns of zero-COVID policy: GlobalData | The Financial Express

China COVID-19 drugs pipeline focuses on new variants amidst rising concerns of zero-COVID policy: GlobalData

According to GlobalData’s Pharma Intelligence Center, there are 19 drugs in various phases of clinical development for the treatment of COVID-19 in China.

China COVID-19 drugs pipeline focuses on new variants amidst rising concerns of zero-COVID policy: GlobalData
In June this year, an open, prospective cohort study of Junshi Biosciences’ VV116 in Chinese patients infected with COVID-19 Omicron variants demonstrated safety and efficacy of the oral antiviral drug within the early onset of infection. (File)

GlobalData, a data and analytics company, on Monday said that as China has reinforced emphasis on its zero-COVID policy, the Chinese companies COVID-19 drugs pipeline is now focusing on new variants.

According to the data analytics company, COVID-19 resurgence in China is a great concern globally due to the presence of two new Omicron sub-variants—BF.7 and BA.5.1.7, as they are highly infectious with greater transmissibility.

According to GlobalData’s Pharma Intelligence Center, there are 19 drugs in various phases of clinical development for the treatment of COVID-19 in China. Of these, five drugs are in Phase III stage. Most of these drugs are targeting various subtypes of COVID-19 variants such as Delta and Omicron, it claimed.

“Notably, the Omicron variants sister lineages BA.5 and BA.2 have shown rise in prevalence and have already spread across at least 25 countries. These variant lineages have been designated by the World Health Organization (WHO) as a ‘variant of concern lineage under monitoring’. Currently, there are only two COVID-19 antiviral drugs, Pfizer’s paxlovid and Genuine Biotech’s azuvidine, marketed in China. Both drugs have shown efficacy against the Omicron variant. However, owing to the rise in COVID-19 cases in China, there will be demand for more antiviral therapies in future, potentially leading to limited supply. In the wake of rising demand, it is important to accelerate clinical development pathway against these variants to allow more access to effective therapies in China,” Anupama Mishra, Pharma Analyst at GlobalData said in a statement on Monday.

In June this year, an open, prospective cohort study of Junshi Biosciences’ VV116 in Chinese patients infected with COVID-19 Omicron variants demonstrated safety and efficacy of the oral antiviral drug within the early onset of infection.

The company also stated that Jushni Bioscience’VV116 is currently being evaluated in Phase III clinical trial for treatment of moderate to severe COVID-19.

Meanwhile, Kintor Pharmaceutical’s proxalutamide has also shown COVID-19 viral load reduction against both delta and Omicron variants in the top-line results of its Phase III clinical trial.

According to GlobalData COVID-19 dashboard, as of 4 November 2022, China had 2,937,390 confirmed cases and 15,605 deaths due to COVID-19. The companies developing COVID-19 drugs in China are preparing themselves to target the emerging variants. Notably, six drug candidates developed by Chinese manufacturers are in late-stage clinical trials, which are targeting Omicron.

“As new COVID-19 variants continue to resurge; it becomes very important for Chinese pharmaceutical companies to align their clinical research towards these variants. The pharmaceutical companies with potential efficacy against the rising new Omicron variants can have potential competitive edge amidst the growing concerns of zero-COVID policy in China,” Mishra added.

ALSO READ | AI-enabled made-in-India products to advance patient care in India: GlobalData

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.

First published on: 07-11-2022 at 14:44 IST